Subtype
Malignant Reproductive System Neoplasm
CI-CAN-00001172Explore in graph →
2,804 active trials38 approved drugs186 evidence items
- NCIt
- C36076
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00001172Explore in graph →
Clinical trials
12,158 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,473)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05255471 | MITO 35B: Olaparib Beyond Progression Compared to Platinum Chemotherapy After Secondary Cytoreductive Surgery in Recurrent Ovarian Cancer Patients.(MITO 35B) | recruiting | Phase 3 | 200 | National Cancer Institute, NaplesOTHER | 1 | Mar 24, 2023 | clinicaltrials |
| NCT01238172 | Diet in Altering Disease Progression in Patients With Prostate Cancer on Active Surveillance | completed | Phase 3 | 478 | Alliance for Clinical Trials in OncologyOTHER | 1 |
| Mar 21, 2023 |
| clinicaltrials |
| NCT05620355 | Efficacy and Safety of BG2109 in Subjects With Heavy Menstrual Bleeding Associated With Uterine Fibroids. | unknown | Phase 3 | 312 | Bio Genuine (Shanghai) Biotech Co., Ltd.INDUSTRY | 1 | Mar 21, 2023 | clinicaltrials |
| NCT02438007 | A Study of Galeterone Compared to Enzalutamide In Men Expressing Androgen Receptor Splice Variant-7 mRNA (AR-V7) Metastatic CRPC(ARMOR3-SV) | terminated | Phase 3 | 953 | LTN PHARMACEUTICALS, INC.INDUSTRY | 8 | Mar 15, 2023 | clinicaltrials |
| NCT02853604 | Study of ADXS11-001 in Participants With High Risk Locally Advanced Cervical Cancer(AIM2CERV) | terminated | Phase 3 | 110 | Advaxis, Inc.INDUSTRY | 14 | Mar 14, 2023 | clinicaltrials |
| NCT03921996 | Extended Pelvic Lymph Node Dissection vs. no Pelvic Lymph Node Dissection at Radical Prostatectomy for intermediate-and High-risk Prostate Cancer | terminated | Phase 3 | 57 | Swiss Cancer InstituteOTHER | 1 | Mar 9, 2023 | clinicaltrials |
| NCT05744115 | Ga-68-PSMA-11 in Men With Prostate Cancer(Ga68-PSMA-11) | terminated | Phase 3 | 38 | Timothy HoffmanFED | 1 | Feb 24, 2023 | clinicaltrials |
| NCT03038100 | A Study of Atezolizumab Versus Placebo in Combination With Paclitaxel, Carboplatin, and Bevacizumab in Participants With Newly-Diagnosed Stage III or Stage IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer(IMagyn050) | completed | Phase 3 | 1,301 | Hoffmann-La RocheINDUSTRY | 22 | Feb 17, 2023 | clinicaltrials |
| NCT00430183 | Surgery With or Without Docetaxel and Leuprolide or Goserelin in Treating Patients With High-Risk Localized Prostate Cancer | active not recruiting | Phase 3 | 788 | Alliance for Clinical Trials in OncologyOTHER | 2 | Feb 9, 2023 | clinicaltrials |
| NCT05244577 | Olanzapine Combined With Fosaprepitant, Ondansetron, and Dexamethasone for Preventing Nausea and Vomiting in Patients With Testicular Cancer | unknown | Phase 3 | 75 | Shi YanxiaOTHER | 1 | Feb 6, 2023 | clinicaltrials |
| NCT04627896 | Targeted Microwave Focal Therapy | completed | Phase 2 / Phase 3 | 11 | A.O.U. Città della Salute e della ScienzaOTHER | 1 | Feb 2, 2023 | clinicaltrials |
| NCT04854993 | Recovery From dNMB Using Different Sugammadex Doses in Elderly Patients Undergoing Robot-assisted Prostatectomy(RECIR) | completed | Phase 3 | 34 | Fondazione Policlinico Universitario Agostino Gemelli IRCCSOTHER | 1 | Jan 25, 2023 | clinicaltrials |
| NCT00033631 | Radiation Therapy in Treating Patients With Stage II Prostate Cancer | completed | Phase 3 | 1,534 | Radiation Therapy Oncology GroupNETWORK | 2 | Jan 18, 2023 | clinicaltrials |
| NCT00055731 | Hormone Therapy With or Without Docetaxel And Estramustine in Treating Patients With Prostate Cancer That is Locally Advanced or At High Risk of Relapse | completed | Phase 3 | 413 | UNICANCEROTHER | 1 | Jan 18, 2023 | clinicaltrials |
| NCT00331773 | Radiation Therapy in Treating Patients With Stage II Prostate Cancer | completed | Phase 3 | 1,116 | Radiation Therapy Oncology GroupNETWORK | 2 | Jan 18, 2023 | clinicaltrials |
| NCT04457245 | Randomized Trial of PSMA PET Scan Before Definitive Radiation Therapy for Prostate Cancer(PSMA-dRT) | terminated | Phase 3 | 54 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Jan 17, 2023 | clinicaltrials |
| NCT03398655 | A Study of VB-111 With Paclitaxel vs Paclitaxel for Treatment of Recurrent Platinum-Resistant Ovarian Cancer (OVAL)(OVAL) | completed | Phase 3 | 408 | Vascular Biogenics Ltd. operating as VBL TherapeuticsINDUSTRY | 5 | Jan 10, 2023 | clinicaltrials |
| NCT00004124 | S9921, Hormone Therapy With or Without Mitoxantrone and Prednisone in Patients Who Have Undergone Radical Prostatectomy for Prostate Cancer | completed | Phase 3 | 983 | SWOG Cancer Research NetworkNETWORK | 1 | Dec 30, 2022 | clinicaltrials |
| NCT00849667 | Efficacy and Safety of Farletuzumab (MORAb-003) in Combination With Carboplatin and Taxane in Participants With Platinum-sensitive Ovarian Cancer in First Relapse | terminated | Phase 3 | 1,100 | MorphotekINDUSTRY | 30 | Dec 30, 2022 | clinicaltrials |
| NCT02745587 | Evaluating the Impact of Prostate Only Versus Pelvic Radiation for N+ Prostate Cancer.(PROPER) | terminated | Phase 3 | 69 | University Hospital, GhentOTHER | 1 | Dec 28, 2022 | clinicaltrials |
| NCT05446883 | QL1706 Plus Chemotherapy±Bevacizumab for the First-Line Treatment of Persistent, Recurrent or Metastatic Cervical Cancer | unknown | Phase 3 | 498 | Qilu Pharmaceutical Co., Ltd.INDUSTRY | 1 | Nov 30, 2022 | clinicaltrials |
| NCT05524389 | Study of Early Stage Endometrial Cancer Based on Molecular Classification and Traditional Risk Stratification to Guide Adjuvant Radiotherapy Decisions | not yet recruiting | Phase 3 | 624 | Peking Union Medical College HospitalOTHER | 0 | Nov 23, 2022 | clinicaltrials |
| NCT05622890 | A Single-arm Clinical Trial of IMGN853 in Chinese Adult Patients With Platinum-resistant, Epithelial Ovarian Cancer | unknown | Phase 3 | 35 | Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.INDUSTRY | 1 | Nov 21, 2022 | clinicaltrials |
| NCT01414608 | Cisplatin and Radiation Therapy With or Without Carboplatin and Paclitaxel in Patients With Locally Advanced Cervical Cancer | completed | Phase 3 | 926 | GOG FoundationNETWORK | 5 | Nov 7, 2022 | clinicaltrials |
| NCT05580341 | Phase III Study Comparing the Immunogenicity of 9-valent HPV Recombinant Vaccine and Gardasil-9 | unknown | Phase 3 | 1,200 | Shanghai Zerun Biotechnology Co.,LtdINDUSTRY | 1 | Oct 28, 2022 | clinicaltrials |
| NCT04026230 | Impact of Atorvastatin on Prostate Cancer Progression During ADT(ESTO2) | unknown | Phase 3 | 400 | Tampere University HospitalOTHER | 4 | Oct 21, 2022 | clinicaltrials |
| NCT03106987 | A Study to Examine Olaparib Maintenance Retreatment in Patients With Epithelial Ovarian Cancer.(OReO) | completed | Phase 3 | 220 | AstraZenecaINDUSTRY | 11 | Oct 7, 2022 | clinicaltrials |
| NCT04237584 | A Study Comparing ARB With Radium-223 vs ARB Therapy With Placebo and the Effect Upon Survival for mCRPC Patients(ESCALATE) | terminated | Phase 3 | 23 | MANA RBMOTHER | 1 | Oct 7, 2022 | clinicaltrials |
| NCT04943627 | Balstilimab Versus Investigator Choice Chemotherapy in Patients With Recurrent Cervical Cancer (BRAVA) | withdrawn | Phase 3 | 0 | Agenus Inc.INDUSTRY | 2 | Oct 5, 2022 | clinicaltrials |
| NCT00943722 | A Study of V503 (A Multivalent Human Papillomavirus [HPV] L1 Virus-Like Particle [VLP] Vaccine) in Preadolescents and Adolescents (V503-002) | completed | Phase 3 | 3,074 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Oct 3, 2022 | clinicaltrials |
| NCT03278717 | Study Evaluating the Efficacy of Maintenance Olaparib and Cediranib or Olaparib Alone in Ovarian Cancer Patients(ICON9) | unknown | Phase 3 | 330 | University College, LondonOTHER | 4 | Sep 27, 2022 | clinicaltrials |
| NCT00377156 | Stereotactic Radiation Therapy With or Without Whole-Brain Radiation Therapy in Treating Patients With Brain Metastases | completed | Phase 3 | 213 | Alliance for Clinical Trials in OncologyOTHER | 2 | Sep 16, 2022 | clinicaltrials |
| NCT05043402 | A Study of Navicixizumab in Patients With Platinum Resistant Ovarian Cancer | unknown | Phase 3 | 400 | OncXerna Theraputics, Inc.INDUSTRY | 0 | Aug 15, 2022 | clinicaltrials |
| NCT04796467 | 68Ga-P16-093 and 68Ga-PSMA-617 PET/CT Imaging in the Same Group of Prostate Cancer Patients | unknown | Phase 2 / Phase 3 | 50 | Peking Union Medical College HospitalOTHER | 1 | Aug 9, 2022 | clinicaltrials |
| NCT05489848 | Chemotherapy vs Chemoradiotherapy for Post-operative Endometrial Cancer Patients With P53-mutation | not yet recruiting | Phase 2 / Phase 3 | 294 | Fudan UniversityOTHER | 0 | Aug 5, 2022 | clinicaltrials |
| NCT05232578 | Early Salvage Therapy for Patients With Advanced Features for Biochemical Relapse After Radical Prostatectomy for Localized Prostate Carcinoma In Correlation With Supposed Molecular-genetic Parameters of Higher Aggressiveness(ESTABLISH) | not yet recruiting | Phase 3 | 380 | General University Hospital, PragueOTHER | 0 | Aug 3, 2022 | clinicaltrials |
| NCT02477644 | Platine, Avastin and OLAparib in 1st Line(PAOLA-1) | completed | Phase 3 | 806 | Arcagy ResearchOTHER | 11 | Aug 2, 2022 | clinicaltrials |
| NCT04520074 | Adjuvant Chemotherapy of Three-step Regimen in BRCA1/2 Wide Type Ovarian Cancer (ACTS-2) | recruiting | Phase 3 | 590 | Fudan UniversityOTHER | 1 | Jul 27, 2022 | clinicaltrials |
| NCT05467319 | Ferric Derisomaltose/Iron Isomaltoside and Outcomes in the Recovery of Gynecologic Oncology ERAS(FORGE) | unknown | Phase 3 | 82 | Alberta Health Services, CalgaryOTHER | 0 | Jul 20, 2022 | clinicaltrials |
| NCT01470677 | Tachosil for the Prevention of Symptomatic Lymph Cysts | completed | Phase 3 | 220 | Ruhr University of BochumOTHER | 2 | Jul 8, 2022 | clinicaltrials |
| NCT03400956 | Assess Safety and Efficacy of Vilaprisan in Subjects With Uterine Fibroids (ASTEROID 4) | terminated | Phase 3 | 103 | BayerINDUSTRY | 5 | Jun 30, 2022 | clinicaltrials |
| NCT02663908 | A Trial Comparing Cardiovascular Safety of Degarelix Versus Leuprolide in Patients With Advanced Prostate Cancer and Cardiovascular Disease(PRONOUNCE) | terminated | Phase 3 | 545 | Ferring PharmaceuticalsINDUSTRY | 12 | Jun 29, 2022 | clinicaltrials |
| NCT00288080 | Hormone Therapy and Radiation Therapy or Hormone Therapy and Radiation Therapy Followed by Docetaxel and Prednisone in Treating Patients With Localized Prostate Cancer | completed | Phase 3 | 612 | Radiation Therapy Oncology GroupNETWORK | 2 | Jun 21, 2022 | clinicaltrials |
| NCT00976911 | AURELIA: A Study of Avastin (Bevacizumab) Added to Chemotherapy in Patients With Platinum-resistant Ovarian Cancer | completed | Phase 3 | 361 | Hoffmann-La RocheINDUSTRY | 14 | Jun 21, 2022 | clinicaltrials |
| NCT03476018 | Trial to Optimally Show the Pharmacological Action of Z-100 | completed | Phase 3 | 72 | Zeria PharmaceuticalINDUSTRY | 1 | Jun 16, 2022 | clinicaltrials |
| NCT00002874 | Radiation Therapy With or Without Bicalutamide for Recurrent pT3N0 Prostate Cancer After Radical Prostatectomy | completed | Phase 3 | 840 | Radiation Therapy Oncology GroupNETWORK | 2 | Jun 15, 2022 | clinicaltrials |
| NCT00005044 | Hormone Therapy and Radiation Therapy in Treating Patients With Prostate Cancer | completed | Phase 3 | 1,579 | Radiation Therapy Oncology GroupNETWORK | 2 | Jun 15, 2022 | clinicaltrials |
| NCT01672892 | Standard Versus Intensity-Modulated Pelvic Radiation Therapy in Treating Patients With Endometrial or Cervical Cancer | completed | Phase 3 | 289 | Radiation Therapy Oncology GroupNETWORK | 4 | Jun 15, 2022 | clinicaltrials |
| NCT05384366 | Neoadjuvant Chemotherapy in Cervical Cancer | completed | Phase 3 | 33 | Banaras Hindu UniversityOTHER | 1 | May 20, 2022 | clinicaltrials |
Data updated 23 days agoSource updated Mar 24, 2023source: clinicaltrials